Skip to main content
OpenTrials
Completed

NCT Number: NCT05328609

An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Hormonal Imbalance

This is an open-label observational trial to study the effectiveness of a commercial dietary supplement and its effect on common symptoms of normal menstrual discomfort.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

About this study

This is an open-label observational trial to study the effectiveness of a commercial dietary supplement and its effect on common symptoms of normal menstrual discomfort.

It is hypothesized that the dietary supplement marketed as The Daily will improve subjective wellbeing in trial participants. It is further hypothesized that the dietary supplement will improve plasma biomarkers that have been previously correlated with insulin resistance.

A total of 45 participants will be recruited for the trial following screening, with the expectation that at least 35 will complete the trial. The trial will be fully remote, and all participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Female, aged 18-55 (roughly 75% 18-38 and 25% 45-55)
  • Ability to take oral medication and be willing to adhere to the dietary supplement regimen (2 capsules per day)
  • Willing to fast overnight (12+ hours) prior to the blood collection, and to perform an at-home fingerprick blood test
  • Moderate self-reported discomfort related to perceived hormone imbalance. Participants must answer B or C on at least 3 of the following questions:

Exclusion criteria

  • Current use of medication for high blood pressure or for blood thinning
  • Diabetic, or on medication such as Metformin or Acarbose
  • Pregnancy, breastfeeding, or attempting to become pregnant during study
  • Known allergic reactions to components of the dietary supplement (sunflower oil, passionflower, berberine, or grape seed extract )
  • Has exercised 3+ times per week of 30 minutes or more per session on average over the past 6 month
  • On a ketogenic or vegan diet for more than the past 30 days
  • If hormonal birth control, cannot stop during the duration of the study.

Treatment and study plan

Semaine Hormonal Imbalance & The Daily

Dietary Supplement

All participants will undergo a menstrual cycle without intervention to establish a baseline, and then will be given the intervention (dietary supplement) for a second menstrual cycle.

Primary outcomes

  1. Discomfort associated with hormone imbalance

    Time frame: 60 days

    Changes in discomfort associated with the most common symptoms linked with perceived hormone imbalance. This outcome measure utilizes a questionnaire using the Likert scale (1-5) with lower values representing an improvement.

Secondary outcomes

  1. Changes in biomarkers linked to insulin sensitivity

    Time frame: 60 days

    Changes in Hemoglobin A1C between baseline and intervention period.

  2. Changes in biomarkers linked to metabolic regulation

    Time frame: 60 days

    Changes in HOMA-IR values between baseline and intervention period.

Other outcomes

  1. Changes in perceived skin quality

    Time frame: 60 days

    Changes in perceived skin quality using skin images of participants' faces to compare changes between baseline and intervention.

Sponsors and collaborators

Lead sponsor

Semaine Health

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Apr 14, 2022
Registry last updated
Oct 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.